Citing positive data from six early-stage studies in its infectious disease portfolio that, it says, builds on the clinical validation of systemic delivery of mRNA, Moderna (NASDAQ:MRNA) has added two programs to its pipeline.
Candidate mRNA-6231: encodes a long-acting selective IL-2 to preferentially expand regulatory T cells that suppress immune activity in autoimmune diseases.
Candidate mRNA-6981: encodes PD-L1 to treat autoimmune disease, initially to be developed in autoimmune hepatitis.
The company has 21 mRNA candidates in its pipeline, including 13 in clinical trials.
#JPM20
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.